In accordance with these results, intranasal administration of OVA resulted in reduced type 2 airway inflammation as illustrated by reduced number of type 2 cytokine-producing CD4 + T cells, eosinophils, and goblet cell hyperplasia in Zbtb46Cre/+Tslprfl/fl mice (Fig. 5f–h). The gene discussed is CD4; the disease is inflammatory response.